多瑞医药
(301075)
| 流通市值：23.13亿 | | | 总市值：23.13亿 |
| 流通股本：8000.00万 | | | 总股本：8000.00万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 278,182,353.51 | 262,128,315.39 | 255,400,920.06 | 271,692,853.48 |
| 应收票据及应收账款 | 100,473,385.27 | 105,956,370.45 | 95,612,720.16 | 104,959,770.82 |
| 其中：应收票据 | - | 3,063,166.09 | 51,992 | 328,423.7 |
| 应收账款 | 100,473,385.27 | 102,893,204.36 | 95,560,728.16 | 104,631,347.12 |
| 应收款项融资 | 249,016.16 | 1,983,141.16 | 1,274,540.6 | 39,138 |
| 预付款项 | 39,625,417.6 | 31,648,271.16 | 36,751,148.34 | 28,007,276.65 |
| 其他应收款合计 | 20,594,260.53 | 19,546,596.23 | 9,698,907.64 | 9,898,253.51 |
| 存货 | 59,104,491.82 | 45,848,529.26 | 60,124,369.99 | 43,822,959.35 |
| 其他流动资产 | 22,620,891.52 | 21,958,877.68 | 14,864,220.59 | 11,665,245.92 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 631,849,224.19 | 630,752,953.83 | 615,258,719.27 | 611,337,482.67 |
| 非流动资产: | | | | |
| 长期股权投资 | 29,843,803.19 | 29,843,803.19 | 100,057,081.08 | 98,415,655.71 |
| 其他权益工具投资 | 78,337,950 | 78,337,950 | 70,795,388.23 | 67,795,388.23 |
| 固定资产 | 622,611,252.64 | 636,670,944.35 | 199,530,897.21 | 192,560,562 |
| 在建工程 | 8,453,907.84 | 5,665,124.1 | 9,931,286.09 | 19,046,741.94 |
| 使用权资产 | 10,466,752.03 | 10,466,752.03 | 2,755,115.02 | 2,755,115.02 |
| 无形资产 | 78,229,838.58 | 78,477,274.65 | 33,375,856.65 | 33,657,575.07 |
| 商誉 | 19,156,743.4 | 19,216,833.03 | 3,892,258.96 | 3,894,710.5 |
| 长期待摊费用 | 2,826,262.95 | 2,835,813.73 | 2,715,737.83 | 2,777,195.26 |
| 递延所得税资产 | 3,093,625.07 | 3,085,790.36 | 1,186,743.32 | 1,208,258.73 |
| 其他非流动资产 | 37,626,182.44 | 39,635,784.65 | 30,505,505.25 | 17,076,562 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 890,646,318.14 | 904,236,070.09 | 454,745,869.64 | 439,187,764.46 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,522,495,542.33 | 1,534,989,023.92 | 1,070,004,588.91 | 1,050,525,247.13 |
| 流动负债: | | | | |
| 短期借款 | 65,935,857.64 | 67,952,297.39 | 25,024,937.5 | 25,024,937.5 |
| 应付票据及应付账款 | 49,465,851.91 | 58,135,609.74 | 42,300,927.04 | 23,671,214.53 |
| 应付账款 | 49,465,851.91 | 58,135,609.74 | 42,300,927.04 | 23,671,214.53 |
| 预收款项 | 1,911,733.82 | 1,250,000 | - | - |
| 合同负债 | 995,365.13 | 2,777,894.79 | 2,398,644.02 | 2,059,769.52 |
| 应付职工薪酬 | 3,807,263.3 | 8,014,207.88 | 3,924,295.43 | 3,595,450.1 |
| 应交税费 | 2,732,781.22 | 2,309,038.45 | 672,002.37 | 3,520,167 |
| 其他应付款合计 | 247,110,540.1 | 247,291,587.7 | 12,394,339.72 | 11,766,007.43 |
| 一年内到期的非流动负债 | 117,766,731.08 | 118,239,863.95 | 46,604,185.5 | 3,598,018.84 |
| 其他流动负债 | 104,869.16 | 3,399,764.08 | 311,823.73 | 267,770.04 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 489,830,993.36 | 509,370,263.98 | 133,631,155.31 | 73,503,334.96 |
| 非流动负债: | | | | |
| 长期借款 | 167,500,000 | 137,500,000 | 165,065,777.78 | 188,118,844.44 |
| 租赁负债 | 7,666,992.57 | 7,213,367.57 | 2,183,024 | 2,183,024 |
| 递延收益 | 106,265,503.86 | 106,897,124.32 | 2,089,053.27 | 2,099,803.26 |
| 递延所得税负债 | 20,475,227.49 | 20,535,317.12 | 888,160.91 | 892,618.26 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 301,907,723.92 | 272,145,809.01 | 170,226,015.96 | 193,294,289.96 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 791,738,717.28 | 781,516,072.99 | 303,857,171.27 | 266,797,624.92 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 80,000,000 | 80,000,000 | 80,000,000 | 80,000,000 |
| 资本公积 | 506,941,221.73 | 506,941,221.73 | 509,053,958.47 | 509,077,457.35 |
| 减:库存股 | 20,991,708.87 | 20,991,708.87 | 20,991,708.87 | 20,991,708.87 |
| 其他综合收益 | 1,137,272.68 | 1,137,272.68 | 676,095.18 | 676,095.18 |
| 盈余公积 | 20,260,274.89 | 20,260,274.89 | 20,260,274.89 | 20,260,274.89 |
| 未分配利润 | 73,785,443.94 | 89,383,609.72 | 134,971,536.73 | 148,773,863.53 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 661,132,504.37 | 676,730,670.15 | 723,970,156.4 | 737,795,982.08 |
| 少数股东权益 | 69,624,320.68 | 76,742,280.78 | 42,177,261.24 | 45,931,640.13 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 730,756,825.05 | 753,472,950.93 | 766,147,417.64 | 783,727,622.21 |
| 负债和股东权益合计 | 1,522,495,542.33 | 1,534,989,023.92 | 1,070,004,588.91 | 1,050,525,247.13 |
| 公告日期 | 2025-04-25 | 2025-04-18 | 2024-10-25 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |